Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.

• Published in: PLoS ONE
• Main Authors: Nygård, Mari, Hansen, Bo Terning, Dillner, Joakim, Munk, Christian, Oddsson, Kristján, Tryggvadottir, Laufey, Hortlund, Maria, Liaw, Kai-Li, Dasbach, Erik J, Kjær, Susanne Krüger
• Format: Article in Journal/Newspaper
• Language: English
• Published: Public Library of Science (PLoS) 2014
• Subjects: Microbiology in the medical area; Norway; Iceland
• Online Access: https://lup.lub.lu.se/record/4335407; https://doi.org/10.1371/journal.pone.0088323; https://portal.research.lu.se/files/3707527/4628826.pdf

Infection with high-risk human papillomavirus (HPV) is causally related to cervical, vulvar and vaginal pre-invasive neoplasias and cancers. Highly effective vaccines against HPV types 16/18 have been available since 2006, and are currently used in many countries in combination with cervical cancer screening to control the burden of cervical cancer. We estimated the overall and age-specific incidence rate (IR) of cervical, vulvar and vaginal cancer and pre-invasive neoplasia in Denmark, Iceland, Norway and Sweden in 2004-2006, prior to the availability of HPV vaccines, in order to establish a baseline for surveillance. We also estimated the population attributable fraction to determine roughly the expected effect of HPV16/18 vaccination on the incidence of these diseases.